IPRsonline.org
Resources
Education
Resources
Resources
Resources



POLICY OPTIONS FOR ASSURING AFFORDABLE ACCESS TO ESSENTIAL MEDICINES
The Bellagio Series on Development and Intellectual Property Policy

At the Rockefeller Foundation's Bellagio Study and Conference Center on Lake Como in Northern Italy,
12 - 16 October 2004

Description | Programme | Participants | Documentation


  Programme


Tuesday 12 October

Welcoming of Participants

Wednesday 13 October

Morning Session: 9:00 - 10:30

Latest developments and trends on IP, health and pharmaceutical data exclusivity
Resource person: Frederick Abbott
Commentator on data exclusivity: Meir Pugatch
Discussion

Morning Session: 10.30 – 13:00

Module I: Explore the effects of current efforts to develop Public Private Partnerships (PPP) as to engage in wider R&D for neglected diseases. The case of HIV, Malaria or Tuberculosis.
Resource person: Roy Widdus
Commentators: Cathy Garner, Gilles Forte and Charles Gardner

Discussion

Afternoon Session: 14:00– 18:00

Module II: Suggesting approaches to facilitate access to medicines through compulsory licensing.
Resource person: Jamie Love
Commentators: Besher N’Daw, Martin Watson and David Vivas-Eugui
Discussion

Thursday 14 October

Morning Session: 9:00 – 13:00

Module III: Creating and promoting domestic drug manufacturing capacities: legal and economic feasibility assessment.
Resource persons: Joan Rovira
Commentators: Rodrigo Salinas, Padmashree Gehl Sampath, Jake Werksman and Muhammadul Haque
Discussion

Afternoon Session: 14:00 – 18:00

Module IV: Competition policy as a tool to address public health concerns. The case of South Africa and Brazil.
Resource persons: Jonathan Berger and Barbara Rosenberg

Commentators: Sisule Musungu, Jamie Love and Shamnad Basheer
Discussion

Friday 15 October

Morning Session: 9:00 – 13:00

Working Groups:

  1. Promoting PPP for R&D in neglected diseases
  2. Facilitating access to medicines through compulsory licensing
  3. Seeking ways for creating and promoting of domestic drug manufacturing capacities
  4. How to strengthen competition policy and institutions as to moderate potential anticompetitive effects of IP in the health field

Afternoon Session: 14:00 – 18:00

Plenary meeting:

  • Presentation of conclusions of Working Groups
  • General discussion on priorities and feasibility of policy actions and research agenda proposed by the Working Groups
  • Adoption of conclusions of the dialogue

Saturday 16 October

Departure of Participants

 

© ICTSD 2004 - Last Update: 05-Oct-2009